tetano
Editor, Senior Moderator
Int Immunopharmacol. 2018 Mar 20;58:109-116. doi: 10.1016/j.intimp.2017.12.020. [Epub ahead of print]
[h=1]Intramuscular and intranasal immunization with an H7N9 influenza virus-like particle vaccine protects mice against lethal influenza virus challenge.[/h] Ren Z[SUP]1[/SUP], Zhao Y[SUP]2[/SUP], Liu J[SUP]2[/SUP], Ji X[SUP]2[/SUP], Meng L[SUP]2[/SUP], Wang T[SUP]2[/SUP], Sun W[SUP]2[/SUP], Zhang K[SUP]2[/SUP], Sang X[SUP]2[/SUP], Yu Z[SUP]2[/SUP], Li Y[SUP]2[/SUP], Feng N[SUP]2[/SUP], Wang H[SUP]2[/SUP], Yang S[SUP]2[/SUP], Yang Z[SUP]3[/SUP], Ma Y[SUP]3[/SUP], Gao Y[SUP]4[/SUP], Xia X[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The H7N9 influenza virus epidemic has been associated with a high mortality rate in China. Therefore, to prevent the H7N9 virus from causing further damage, developing a safe and effective vaccine is necessary. In this study, a vaccine candidate consisting of virus-like particles (VLPs) based on H7N9 A/Shanghai/2/2013 and containing hemagglutinin (HA), neuraminidase (NA), and matrix protein (M1) was successfully produced using a baculovirus (BV) expression system. Immunization experiments showed that strong humoral and cellular immune responses could be induced by the developed VLPs when administered via either the intramuscular (IM) or intranasal (IN) immunization routes. Notably, VLPs administered via both immunization routes provided 100% protection against lethal infection caused by the H7N9 virus. The IN immunization with 40μg of H7N9 VLPs induced strong lung IgA and lung tissue resident memory (TRM) cell-mediated local immune responses. These results provide evidence for the development of an effective preventive vaccine against the H7N9 virus based on VLPs administered through both the IM and IN immunization routes.
[h=4]KEYWORDS:[/h] H7N9 influenza; Immunogenicity; Mucosally vaccinated; Virus-like particles
PMID: 29571081 DOI: 10.1016/j.intimp.2017.12.020
[h=1]Intramuscular and intranasal immunization with an H7N9 influenza virus-like particle vaccine protects mice against lethal influenza virus challenge.[/h] Ren Z[SUP]1[/SUP], Zhao Y[SUP]2[/SUP], Liu J[SUP]2[/SUP], Ji X[SUP]2[/SUP], Meng L[SUP]2[/SUP], Wang T[SUP]2[/SUP], Sun W[SUP]2[/SUP], Zhang K[SUP]2[/SUP], Sang X[SUP]2[/SUP], Yu Z[SUP]2[/SUP], Li Y[SUP]2[/SUP], Feng N[SUP]2[/SUP], Wang H[SUP]2[/SUP], Yang S[SUP]2[/SUP], Yang Z[SUP]3[/SUP], Ma Y[SUP]3[/SUP], Gao Y[SUP]4[/SUP], Xia X[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The H7N9 influenza virus epidemic has been associated with a high mortality rate in China. Therefore, to prevent the H7N9 virus from causing further damage, developing a safe and effective vaccine is necessary. In this study, a vaccine candidate consisting of virus-like particles (VLPs) based on H7N9 A/Shanghai/2/2013 and containing hemagglutinin (HA), neuraminidase (NA), and matrix protein (M1) was successfully produced using a baculovirus (BV) expression system. Immunization experiments showed that strong humoral and cellular immune responses could be induced by the developed VLPs when administered via either the intramuscular (IM) or intranasal (IN) immunization routes. Notably, VLPs administered via both immunization routes provided 100% protection against lethal infection caused by the H7N9 virus. The IN immunization with 40μg of H7N9 VLPs induced strong lung IgA and lung tissue resident memory (TRM) cell-mediated local immune responses. These results provide evidence for the development of an effective preventive vaccine against the H7N9 virus based on VLPs administered through both the IM and IN immunization routes.
[h=4]KEYWORDS:[/h] H7N9 influenza; Immunogenicity; Mucosally vaccinated; Virus-like particles
PMID: 29571081 DOI: 10.1016/j.intimp.2017.12.020